Navigation

2003/047 NICE issues guidance on newer drugs for bipolar disorder

The National Institute for Clinical Excellence has issued guidance on the use of two drugs for treatment of acute mania associated with bipolar I disorder.

In summary, the guidance recommends that olanzapine and valproate semisodium (used as licensed) should be considered as options among the medicines available for the treatment of the acute symptoms of mania associated with bipolar I disorder. The choice of drug should be made jointly by the individual and their doctor after a discussion of the benefits and possible side-effects of each treatment and should take into account the needs of the individual and their particular clinical situation.

This page was last updated: 29 April 2009

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.